Advancing best-in-
class and first-in-class candidates
IAM1363
HER2
IAM1363 is a highly potent and irreversible tyrosine kinase inhibitor (TKI) that selectively targets HER2 and HER2 mutants, while sparing EGFR. Amplification and mutations of HER2 drive a wide range of human cancers. HER2 TKIs have had limited success due to a compensatory mechanism that increases the required therapeutic index beyond that of available pan-ERBB and HER2 inhibitors.
IAM1363 exhibits over 5000-fold selectivity against EGFR, favorable PK and safety profiles, preferential tumor enrichment, and effective CNS penetrance. Together these make IAM1363 a breakthrough molecule for realizing the full therapeutic potential of inhibiting HER2 signaling, while avoiding EGFR-driven toxicity. In vivo, IAM1363 has demonstrated favorable efficacy and tolerability across a range of HER2 tumor models, including intracranial models, outperforming benchmark TKIs and antibody-drug conjugates (ADCs).
IAM1363 is currently in a multi-center Phase 1b study.
IAM-K1
KIF18A
KIF18A is a kinesin that helps regulate microtubule dynamics in the cell cycle metaphase. In healthy dividing cells there is little reliance on KIF18A, whereas chromosomally unstable tumor cells are critically dependent on it. Inhibition of this motor protein has potential for strong anti-proliferative effect across a wide range of solid tumors, while sparing healthy dividing cells.
IAM-K1 is a potential best-in-class KIF18A inhibitor for triple-negative breast cancer, ovarian cancer, and other solid tumor indications. We have designed this allosteric inhibitor with a differentiated profile for excellent ADME and PK properties, a clean DDI profile, and brain-penetrance.
We are rapidly advancing IAM-K1 to become a clinical-stage candidate as we see the opportunity to demonstrate strong anti-tumor activity and efficacy in patients with brain metastases, supported by a biomarker-specific and differentiated clinical path.
IAM-C1
CDK2/4
IAM-C1 is a small-molecule inhibitor with a potential first-in-class selectivity profile, designed to specifically target CDK2 and CDK4, two cell-cycle kinases that are frequently dysregulated in various cancers. IAM-C1 has been designed to expand the therapeutic potential compared to clinically approved CDK4/6 inhibitors in HR+/HER2 breast cancer, the most common subtype.
CDK4/6 inhibitors are standard of care for HR+/HER2-metastatic breast cancer patients in the front- and later-line settings. Despite the success of these agents, many patients demonstrate either intrinsic or acquired resistance to the approved CDK4/6 inhibitors, leading to mortality, resulting in significant unmet medical need.
The unique profile of IAM-C1, achieved through novel structural engagement, is anticipated to demonstrate increased activity, improved durability, and improved tolerance compared to CDK4/6 inhibitors.
Undisclosed
Undisclosed
Undisclosed
Delivering development candidates years faster than industry norms
Leverage our platform within your program
Imagine creating thousands of novel molecular designs and a read out of new biological data on a weekly cadence. By directing our powerful AI tools towards your high priority targets, we drive through chemical space to identify unique and highly differentiated development candidates on a time scale far faster than industry average.
